isopropyl-[1-(4-isopropoxypyridin-3-ylmethyl)piperidin-4-yl]amine | 690998-92-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: isopropyl-[1-(4-isopropoxypyridin-3-ylmethyl)piperidin-4-yl]amine
• 英文别名: N-propan-2-yl-1-[(4-propan-2-yloxypyridin-3-yl)methyl]piperidin-4-amine
• CAS: 690998-92-6
• 化学式: C₁₇H₂₉N₃O
• 分子量: 291.437
• InChiKey: WJWBIIKFABRMJA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  21
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  37.4
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Substituted 4-amino-1-(pyridylmethyl)piperidine and related compounds
  申请人：——

  公开号：US20040122014A1

  公开（公告）日：2004-06-24

  This invention provides 4-amino-1-(pyridylmethyl)piperidine and related compounds and pharmaceutically acceptable salts thereof which are useful as muscarinic receptor antagonists. This invention also provides pharmaceutical compositions containing such compounds; processes and intermediates useful for preparing such compounds; and methods for treating disease conditions mediated by muscarinic receptors, such as overactive bladder, irritable bowel syndrome and chronic obstructive pulmonary disease, using such compounds.

  本发明提供了4-氨基-1-(吡啶甲基)哌啶及其相关化合物和药物可接受的盐，这些化合物可用作毒蕈碱受体拮抗剂。本发明还提供了含有这些化合物的药物组合物；用于制备这些化合物的工艺和中间体；以及使用这些化合物治疗由毒蕈碱受体介导的疾病状况，如过度活跃的膀胱、肠易激综合征和慢性阻塞性肺疾病的方法。
• SUBSTITUTED 4-AMINO-1-(PYRIDYLMETHYL) PIPERIDINE AS MUSCARINIC RECEPTOR ANTAGONISTS
  申请人：Theravance, Inc.

  公开号：EP1556372A2

  公开（公告）日：2005-07-27
• US7285564B2
  申请人：——

  公开号：US7285564B2

  公开（公告）日：2007-10-23
• US8030502B2
  申请人：——

  公开号：US8030502B2

  公开（公告）日：2011-10-04
• [EN] SUBSTITUTED 4-AMINO-1-(PYRIDYLMETHYL)PIPERIDINE AND RELATED COMPOUNDS<br/>[FR] 4-AMINO-1-(PYRIDYLMETHYL) PIPERIDINE SUBSTITUEE ET COMPOSES ASSOCIES
  申请人：THERAVANCE INC

  公开号：WO2004041806A2

  公开（公告）日：2004-05-21

  This invention provides 4-amino-1-(pyridylmethyl) piperidine of formula (I) and related compounds and pharmaceutically acceptable salts thereof which are useful as muscarinic receptor antagonists. This invention also provides pharmaceutical compositions containing such compounds; processes and intermediates useful for preparing such compounds; and methods for treating disease conditions mediated by muscarinic receptors, such as overactive bladder, irritable bowel syndrome and chronic obstructive pulmonary disease, using such compounds.